EMA Prepared Systems for New Biotech Legislation
The European Medicines Agency is updating its clinical trial infrastructure to support upcoming pharmaceutical reforms.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust that EU regulators will effectively manage the transition to modernized medical authorization systems?
During its September 2026 meeting, the European Medicines Agency (EMA) board reviewed progress on operational updates and established procedures for selecting its next Executive Director. These moves prepare the agency for regulatory shifts under the Biotech Act, which the European Commission proposed in December 2025.
Why it matters
The EMA is modernizing its regulatory processes to ensure the reliable supply and availability of critical medicines across Europe. These adjustments align institutional capacity with the pending pharmaceutical legislation aimed at accelerating clinical development timelines.
The agency’s Clinical Trials Information System (CTIS) has supported over 14,000 clinical trials since 2022 and currently manages a volume of 200 new applications per month. These digital systems must now be overhauled, as 70% of existing CTIS functionality faces modification under the proposed rules.
The players
European Medicines Agency
The decentralized EU body responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
European Commission
The executive branch of the European Union responsible for proposing legislation and implementing union policies.
The details
The EMA maintains the CTIS, a centralized online portal used by sponsors to submit clinical trial applications and by national regulators to perform joint assessments. To comply with the Biotech Act, the agency must re-engineer this platform to integrate with new requirements for pharmaceutical data submission and regulatory oversight. Development of this modernized platform is slated to begin in early 2027 to ensure technical readiness for shifting clinical trial regulations.
Timeline
January to June 2026: Period for the 29 new human medicine applications and 7 veterinary applications.
September 2026: The EMA Management Board held its progress review meeting.
December 2026: The agency will present a detailed roadmap for the CTIS updates.
Early 2027: Work begins on the upgraded clinical trial platform.
Early 2028: Implementation of clinical trial regulation changes may occur.
The Tech Race
The EMA’s effort to overhaul the CTIS platform follows the December 2025 Biotech Act proposal from the European Commission. This initiative represents a critical institutional race to align digital regulatory infrastructure with the continent's new pharmaceutical framework.
These regulatory changes aim to improve the long-term availability of medicine across the European Union by streamlining the administrative burden for trial sponsors. Stakeholders, including pharmaceutical developers, should monitor the upcoming roadmap release in December for specific technical requirements.
The takeaway
The EMA is shifting its focus toward a fully modernized trial infrastructure to support the upcoming Biotech Act mandates. Researchers and sponsors should look for the official platform roadmap in December 2026 as a primary indicator of how digital submission workflows will evolve.
What happens next
The EMA will hold a detailed presentation regarding the CTIS platform roadmap in December 2026.
Further reading
For more on the current landscape of regulatory technology, visit Biotech.
Source note: This article includes information reported by European Medicines Agency (EMA).
Live Poll
Do you trust that EU regulators will effectively manage the transition to modernized medical authorization systems?
